Revefenacin
Yupelri (revefenacin) is a small molecule pharmaceutical. Revefenacin was first approved as Yupelri on 2018-11-09. It is used to treat chronic obstructive pulmonary disease in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, and muscarinic acetylcholine receptor M5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Yupelri
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| yupelri | New Drug Application | 2022-05-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| chronic obstructive pulmonary disease | EFO_0000341 | D029424 | J44.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Revefenacin, Yupelri, Mylan Ireland Ltd | |||
| 11484531 | 2039-10-23 | U-2440 | |
| 8541451 | 2031-08-25 | DP | |
| 9765028 | 2030-07-14 | DP | |
| 10550081 | 2030-07-14 | DP | |
| 11008289 | 2030-07-14 | U-2440 | |
| 11691948 | 2030-07-14 | DP | |
| 11858898 | 2030-07-14 | DS, DP | U-2440 |
| 7288657 | 2025-12-23 | DP | |
| 7491736 | 2025-03-10 | U-2440 | |
| 7521041 | 2025-03-10 | U-2440 | |
| 7550595 | 2025-03-10 | DP | |
| 7585879 | 2025-03-10 | DS, DP | U-2440 |
| 7910608 | 2025-03-10 | DS, DP | |
| 8034946 | 2025-03-10 | DP | |
| 8053448 | 2025-03-10 | U-2440 | |
| 8273894 | 2025-03-10 | DP | |
| 10106503 | 2025-03-10 | U-2440 | |
| 10343995 | 2025-03-10 | U-2440 | |
| 11247969 | 2025-03-10 | DP | |
HCPCS
Code | Description |
|---|---|
| J7677 | Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram |
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | 5 | 6 | 1 | — | 14 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | 4 | 6 | 1 | — | 12 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 4 | 5 | 1 | — | 10 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | 1 | — | 1 | 1 | — | 3 |
| Disease progression | D018450 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Revefenacin |
| INN | revefenacin |
| Description | Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.
|
| Classification | Small molecule |
| Drug class | muscarinic receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 1211931-83-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3833319 |
| ChEBI ID | — |
| PubChem CID | 11753673 |
| DrugBank | DB11855 |
| UNII ID | G2AE2VE07O (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CHRM2
CHRM2
CHRM1
CHRM1
CHRM4
CHRM4
CHRM3
CHRM3
CHRM5
CHRM5
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Yupelri – Theravance Biopharma
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Yupelri – Viatris
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 87 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
237 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use